Towards Healthcare
U.S. Exosomes Market Size | Companies | 34.22% - CAGR Growth

U.S. Exosomes Market Size to Reach USD 1,428.79 Mn by 2033

The report covers U.S. Exosomes Market Segments in terms of product type such as kits & reagents, instruments and services. Workflow types include isolation methods like ultracentrifugation, immunocapture on beads, precipitation, filtration and others, as well as downstream analysis methods such as cell surface marker analysis using flow cytometry, protein analysis using blotting & ELISA, RNA analysis with NGS & PCR, proteomic analysis using mass spectrometry and others. Application areas encompass cancer, neurodegenerative diseases, cardiovascular diseases, infectious diseases and others. End-use sectors include pharmaceutical & biotechnology companies, hospitals & diagnostics centers and academic & research institutes. The report offers the value (in USD Million) for the above segments.

U.S. Exosomes Market Size, Manufacturers and Growth Overview

The U.S. exosomes market was valued at US$ 75.30 million in 2023 and is projected to reach US$ 1,428.79 million by 2033, registering a CAGR of 34.22% from 2024 to 2033. The increasing number of cases of chronic conditions is driving the growth of the U.S. exosomes market.

U.S. Exosomes Market Revenue 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • By product, the kits & reagents segment has held a major revenue share of 46% in 2023.
  • By product, the services segment is expected to expand at the fastest CAGR of 33.02% over the forecast period.
  • By workflow, the downstream analysis segment held the largest market share in 2023.
  • By workflow, the isolation methods segment is anticipated to grow at a significant rate during the forecast period.
  • By application, the cancer segment led the market with the largest revenue share of 33% in 2023.
  • By application, the infectious diseases segment is projected to grow at the solid CAGR of 35.01% during the forecast period of 2024-2033.
  • By end-user, the pharmaceutical & biotechnology companies segment dominated the U.S. exosomes market in 2023.

Industry at a Glance

The U.S. exosomes market is expanding because of the increasing use of exosomes in diagnosing and treating various diseases and health conditions. Exosomes belong to a group of extracellular vesicles that come from the endosomal system and usually measure between 30 to 150 nanometers in size, making them the smallest kind of extracellular vesicle. These vesicles are surrounded by a lipid bilayer and are released into the surrounding space, carrying a mix of complex materials from the cell they originated from, such as proteins, lipids, mRNA, miRNA, and DNA. They serve the function of transporting and exchanging different substances between cells and are utilized as non-invasive indicators for various diseases.

Top Companies in the U.S. Exosomes Market

  • Aethlon Medical
  • Aegle Therapeutics Corporation
  • Coya Therapeutics
  • Capricor Therapeutics
  • Aragen Bioscience
  • RoosterBio, Inc
  • Bio-Techne
  • Hologic Inc.
  • Thermo Fisher Scientific, Inc.
  • Celularity Inc.
  • Danaher

Celularity Inc. Pipeline in Exosomes Application

Company Name Celularity Inc.
Headquarters New Jersey, U.S.
Pipeline The firm is working on creating placental exosomes (pExo) as possible therapies that can transport growth-promoting factors, aiding in the formation of neural cells, blood vessels, and muscle tissue. pExo shows specific markers for exosomes, such as CD9, CD63, and CD81, and holds more than a thousand unique proteins and microRNAs that play roles in various biological processes. pExo includes various types of cytokines and chemokines and helps grow primary human cells from various organs and tissues. The pExo pipeline is currently being assessed for potential uses in treating regenerative and age-related conditions at the pre-clinical level.

Aethlon Medical Pipeline in Exosomes Application

Company Name Aethlon Medical
Headquarters California, U.S.
Pipeline In May 2024, the company announced the positive results of the phase I trial of Hemopurifier®. It will now move to the next stage. Designed to quickly reduce circulating viruses and exosomes that promote cancer, the Aethlon Hemopurifier® is a pioneering technology. The Hemopurifier® is a "Breakthrough Device" according to the FDA, meaning that it can be used to treat patients with life-threatening viruses that are not treated by approved therapies, as well as patients with advanced or metastatic cancer who are either intolerant of or unresponsive to standard-of-care therapy.

The Different Applications of Exosomes are Driving the Growth of the U.S. Exosomes Market

The Different Applications of Exosomes are Driving the Growth of the U.S. Exosomes Market

Exosomes are vesicles released from cells that are crucial for communication between cells and are found in many bodily fluids such as blood, saliva, urine, and cerebrospinal fluid, among others. Exosomes are evidently occurring compounds that may withstand digestive enzymes because of the innate residences of exosomes, including their capability tissue of mobile selectivity. The capability to go blood-mind barriers causes fewer systemic consequences and occasional toxicity. These vesicles are particularly well-suited for cancer detection due to their distinct features. They are also valuable in predicting and identifying a range of illnesses, including cancer, heart and age-related diseases, arthritis, brain disorders, and diabetes.

Additionally, exosomes are utilized in medical research and early-stage clinical studies. In recent years, cures using extracellular vesicles have garnered substantial attention among industry stakeholders to remedy numerous target warning signs, generally owing to their numerous applications, including goal specificity, more advantageous tissue regeneration, and reduced irritation and chronic pain.

For instance,

  • In February 2024, announced the launch of a Phase I/II clinical trial to study AB126, an allogeneic neural exosome produced from neural stem cells, which is something that biotechnology company Aruna Bio (GA, U.S.) is committed to doing for the treatment of neurogenerative illness. Collaborating with scientists from the Regenerative Bioscience Center at the University of Georgia (UGA; GA, U.S.), the trial aims to assess the drug's preliminary effectiveness, safety, and tolerability in patients with ischemic stroke who have a poor prognosis after thrombectomy.

Lack of Regulatory Standards May Restraint the Growth of the U.S. Exosomes Market

There are currently no guidelines for exosome research, which is still in its early stages. Because of this, professionals adopt new methods and procedures that are readily available on the market without any hesitation. Mistakes committed during the synthesis of exosomes are not the only challenges scientists face throughout exosome research, development, and manufacturing. MSC-derived exosomes have garnered significant interest in recent times due to their ability to function as intercellular messengers. Their unique property makes them attractive for scientific applications such as medication delivery, gene therapy, vaccine research, and cancer diagnostics. Therefore, inventors of MSC-exosome treatments must modify their stem cell-free therapy method to accommodate the new exosome manufacturing process in order to produce effective exosome harvesting procedures and set industry-leading standards for exosome characterization and purification.

The U.S. Exosomes Market Has Opportunity in Medical Aesthetics

The primary goals of medical aesthetics include wound healing, anti-aging, preventing hyperpigmentation, and hair loss prevention. Exosomes have the power to influence apoptosis, angiogenesis, inflammation, and the growth and differentiation of cells. As a result, their applications in dermatology may be extensive. Exosomes may be used in dermatology for a variety of purposes, including hair growth, skin rejuvenation, pigmentation management, and scar prevention and therapy. Exosome applications in aesthetics are still in their early stage, and more studies might reveal new advantages and improve current therapies. Scientists are investigating ways to modify exosomes to deliver particular therapeutic payloads customized to meet the requirements of individual patients as technology develops. This customized strategy might precisely address particular issues.

For instance,

  • In May 2024, Elevai Labs, Inc., a leader in medical aesthetics, announced the launch of Elevai Biosciences, Inc. and Elevai Skincare, Inc., two new wholly-owned subsidiaries. These initiatives represent a strategic turn toward the creation of cutting-edge cosmetic medications and initiatives to strengthen the financial position of its well-known exosome skincare brand.

Report Highlights

Product Insights

By product insights, the kits & reagents segment dominated the U.S. exosomes market in 2023. The isolation of exosomes is necessary for different applications, and this is achieved with the help of kits and reagents. Tying up water molecules by polymer precipitation decreases the solubility of exosomes and causes their precipitation, which in turn allows exosomes to be isolated from cells and heavy debris. After a low-speed centrifugation process, exosomes are extracted. By using this technique, Total Exosome Isolation reagents and kits facilitate the expeditious extraction of exosomes, starting with the collection of samples. Processing small sample quantities and managing numerous samples are just two of the many applications that may benefit greatly from the Total Exosome Isolation kits, chemicals, and procedures that go along with them.

Workflow Insights

By workflow insights, the downstream analysis segment held the largest U.S. exosomes market share in 2023. Cell surface marker analysis using flow cytometry, proteomic analysis using mass spectroscopy, protein Analysis using blotting & ELISA, and RNA analysis with NGS & PCR come under downstream analysis. Isolating, purifying, and concentrating the previously produced medicinal molecule or other product from the intricate bulk matrix is the aim of downstream processing. Optimizing the recovery of hMSC extracellular vesicles from the upstream program while eliminating impurities is the goal of scalable downstream processing. For exosomes to be a useful class of therapeutics, improvements in both upstream and downstream processes are required. Differential DNA and RNA expression between the illness and control is the most popular downstream use of exosomes. Producing biopharmaceuticals that are both safe and effective requires downstream processing. For patient safety and regulatory clearance, the finished product's purity and quality are essential.

According to workflow insights, the isolation methods segment is anticipated to grow at a significant rate during the forecast period. A diverse array of donor cells, such as tumor cells, macrophages, dendritic cells (DCs), and mesenchymal stem cells (MSCs), have been found to produce exosomes. A deeper comprehension of exosome properties and functions is critically needed, as they are involved in cellular interactions on a universal scale. As such, the present focus is on isolating exosomes and analyzing them biologically and genetically. Approximately 80% of exosome researchers worldwide still employ ultracentrifugation (which includes differential centrifugation) as their principal method of exosome separation.

For instance,

  • In May 2024, creative Biolabs launched an exosome-based platform that provides a multitude of services, such as exosome manufacture, engineering, and analysis. The platform has expedited the client's exosome research procedures considerably. It is a complete, one-stop-shop made to accommodate the different requirements of different types of investigations. In order to produce high-purity, high-quality exosomes, Creative Biolabs' exosome research platform also includes exosome engineering and manufacturing services, such as ultracentrifugation, ultrafiltration, size-exclusion chromatography, and immunoaffinity capture for exosome isolation.

Application Insights

By application insights, the cancer segment dominated the market with the largest U.S. exosomes market share in 2023. Exosomes released by cancer cells have been shown in several studies to possess distinctive molecules that serve as molecular markers for cancer detection as well as a means of differentiating one exosome from another. Common molecular detection indicators found in exosomes that can be used to diagnose cancer include nucleic acids and proteins. It has been discovered that a variety of exosome protein indicators are helpful in the early detection of cancer and prognostic risk assessment. Other nucleic acid molecules contained in exosomes have also been shown to be helpful indicators for cancer detection, in addition to miRNA-like ones. Exosomes can be utilized in cancer treatment and can offer molecular detection markers for cancer diagnosis. Exosomes may transport a variety of medications, including lipids, proteins, nucleic acids, or other small molecule compounds, and are also useful as carriers of cancer therapies.

The major reason for the growth of the U.S. exosomes market is the increasing number of cancer cases in the U.S. According to the National Cancer Institute, around 2.0 million people are estimated to have cancer in the U.S.. Among all the cancers, breast cancer is the most common, with 310,720 women and 2,790 men being diagnosed with it. It is estimated that 611,720 people will die due to cancer in 2024 in the U.S.

Estimated New Cancer Cases in the U.S., 2024

By application insights, the infectious diseases segment is estimated to grow at the fastest CAGR during the forecast period of 2024-2033. Exosomes have a significant influence on how infections turn out. The phase and source of the cells that exosomes' biological role type and efficiency are determined by their genesis. Exosomes should be considered suitable candidates for creating a vaccine that can be used for both prevention and therapy since they contribute to the spreading and limiting of an illness. Using exosomes formed from APCs challenged by infections or developing vaccines based on containing microbial antigens as a strong adjuvant in conjunction with immune cells may be effective and less harmful long-term therapies. There is an additional potential that identifying substances with the ability to trigger the release of particular exosomes specifically might be beneficial in inhibiting infection and managing detrimental outcomes.

By End-User Insights

By end-user, the pharmaceutical & biotechnology companies segment dominated the U.S. exosomes market in 2023. As a result, much thought has been given to the creation of exosome-based nano-theranostic techniques for improving illness prognosis and therapeutic approaches. Exosomes are a special kind of nanoparticulate carrier for pharmaceutical medication delivery because of their advantageous biopharmaceutical characteristics. The pharmaceutical and biotech industries are getting closer to utilizing exosomes' therapeutic qualities to combat or deliver medications that will combat illnesses and viruses as our understanding of exosome biology and function grows. Exosomes now exhibit promise for use in a range of scientific, medical, and therapeutic contexts. Preclinical research is showing strong impacts, and preliminary clinical data is showing promising safety and effectiveness outcomes. Exosomes may be used as a delivery vehicle for proteins or nucleic acid payloads in medical treatments that target illnesses, alter immune responses, and restore tissue.

Recent Developments in the U.S. Exosomes Market

  • In November 2023, the Department of Defense gave a $2.4 million grant to RION, a prominent clinical-stage regenerative medicine business, which will work with the Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on the project. With the help of this grant, a vital research project to investigate the therapeutic potential of RION's exclusive Purified Exosome ProductTM (PEPTM) is accelerated. These conditions include Chronic Obstructive Pulmonary Disease (COPD) and other difficult pulmonary diseases that can affect veterans and soldiers who have been exposed to flying hazards in combat zones.
  • In September 2022, platelet-derived exosomes were used for cosmetics and restorative therapeutic applications by RION AESTHETICS, a business that pioneered stem cell aesthetics. The clinical outcomes of a recent cosmetic research that treated aged skin with platelet-derived exosome technology were revealed. Exosome technology, when it comes to aesthetics, is redefining skincare innovation by giving customers access to a naturally derived substance that effectively targets the signs of aging skin.

Segments Covered in the Report

By Product Type

  • Kits & Reagents
  • Instruments
  • Services

By Workflow Type

  • Isolation Methods
    • Ultracentrifugation
    • Immunocapture on Beads
    • Precipitation
    • Filtration
    • Others
  • Downstream Analysis
    • Cell Surface Marker Analysis using Flow Cytometry
    • Protein Analysis using Blotting & ELISA
    • RNA Analysis with NGS & PCR
    • Proteomic Analysis using Mass Spectroscopy
    • Others

By Application Type

  • Cancer
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

By End-use Type

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Diagnostics Centers
  • Academic & Research Institutes

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.


Exosomes are used to deliver proteins, lipids and nucleic acid during circulation in the extracellular spaces.

In the future, exosomes can be used as biomarkers for diagnosis and treatment of disease. Due to their capability to pass the blood-brain barrier, they can also be used in the analysis of brain-related diseases or conditions.

American Cancer Society, National Cancer Institute, National Institutes of Health and FDA.